The scientist’s investigation covers issues in Virology, Hepatitis C virus, Sofosbuvir, Hepatitis C and Ribavirin. His Virology research is multidisciplinary, incorporating elements of Protease and Genotype. His Hepatitis C virus research incorporates elements of Replicon and Clinical trial.
His Sofosbuvir study incorporates themes from Ledipasvir, Internal medicine, Voxilaprevir and NS5B. His Internal medicine research includes elements of Gastroenterology and Surgery. His Ribavirin study combines topics in areas such as Tolerability and Pharmacology.
His primary areas of study are Virology, Hepatitis C virus, Genotype, Sofosbuvir and Internal medicine. His study ties his expertise on Replicon together with the subject of Virology. His Hepatitis C virus research is multidisciplinary, relying on both Hepatitis C, Viral load, Clinical trial and Pharmacology.
His work carried out in the field of Hepatitis C brings together such families of science as Tolerability, Drug resistance and Cohort. As part of the same scientific family, he usually focuses on Sofosbuvir, concentrating on Ledipasvir and intersecting with Fixed-dose combination and Daclatasvir. His Internal medicine research incorporates themes from Gastroenterology and Surgery.
His main research concerns Virology, Hepatitis C virus, Genotype, Sofosbuvir and Internal medicine. His Virology study combines topics from a wide range of disciplines, such as Genotyping and In vitro. The study incorporates disciplines such as Interferon and Deep sequencing in addition to Hepatitis C virus.
His research integrates issues of NS3 and Viral load in his study of Genotype. Hongmei Mo combines subjects such as Ledipasvir, Cirrhosis, Regimen and Hepacivirus with his study of Sofosbuvir. Hongmei Mo has included themes like Gastroenterology and Sofosbuvir/velpatasvir in his Internal medicine study.
Hongmei Mo mainly investigates Sofosbuvir, Hepatitis C virus, Internal medicine, Ledipasvir and Genotype. Virology and Ribavirin are closely tied to his Sofosbuvir research. As a member of one scientific family, he mostly works in the field of Hepatitis C virus, focusing on Discontinuation and, on occasion, Cirrhosis.
In his study, which falls under the umbrella issue of Internal medicine, Viral load is strongly linked to Gastroenterology. His Ledipasvir study integrates concerns from other disciplines, such as Daclatasvir and Drug resistance. The Genotype study which covers Clinical trial that intersects with Incidence, Viremia, Virus and Immunology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Nezam Afdhal;Stefan Zeuzem;Paul Kwo;Mario Chojkier.
The New England Journal of Medicine (2014)
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
Graham R. Foster;Nezam Afdhal;Stuart K. Roberts;Norbert Bräu.
The New England Journal of Medicine (2015)
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.
Eric Lawitz;Fred F Poordad;Phillip S Pang;Robert H Hyland.
The Lancet (2014)
David A. Betebenner;David A. Degoey;Clarence J. Maring;Allan C. Krueger.
Official Gazette of the United States Patent and Trademark Office Patents (2011)
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.
Masashi Mizokami;Osamu Yokosuka;Tetsuo Takehara;Naoya Sakamoto.
Lancet Infectious Diseases (2015)
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
Eric Lawitz;Jay P Lalezari;Tarek Hassanein;Kris V Kowdley.
Lancet Infectious Diseases (2013)
Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor.
D. D. Ho;T. Toyoshima;Hongmei Mo;D. J. Kempf.
Journal of Virology (1994)
Hepatitis C virus drug resistance–associated substitutions: State of the art summary
Erik Lontok;Patrick Harrington;Anita Howe;Tara Kieffer.
Mutations Conferring Resistance to a Potent Hepatitis C Virus Serine Protease Inhibitor In Vitro
Liangjun Lu;Tami J. Pilot-Matias;Kent D. Stewart;John T. Randolph.
Antimicrobial Agents and Chemotherapy (2004)
Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor.
M. Markowitz;Hongmei Mo;D. J. Kempf;D. W. Norbeck.
Journal of Virology (1995)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: